Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$2.63
-0.07-2.59%
At close: Jul 10, 5:00 PM EST
$2.60
-0.03-1.14%
After Hours: Jul 10, 6:24 PM EST
Acumen Pharmaceuticals Inc Analyst Ratings
ABOSNASDAQ
Acumen Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:ABOS | Benzinga
Acumen Pharmaceuticals Inc has a consensus price target of $8.44 based on the ratings of 9 analysts. The high is $13 issued by Credit Suisse on August 9, 2023. The low is $4 issued by Citigroup on June 17, 2025. The 3 most-recent analyst ratings were released by BTIG on March 26, 2026, March 16, 2026, and January 27, 2026, respectively. With an average price target of $7.67 between BTIG, there's an implied 194.87% upside for Acumen Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
BTIG
B of A Securities
Citigroup
UBS
HC Wainwright & Co.
1calculated from analyst ratings
Analyst Ratings for Acumen Pharmaceuticals
Loading calendar...
FAQ
What is the target price for Acumen Pharmaceuticals (ABOS) stock?
The latest price target for Acumen Pharmaceuticals (NASDAQ:ABOS) was reported by BTIG on March 26, 2026. The analyst firm set a price target for $8.00 expecting ABOS to rise to within 12 months (a possible 207.69% upside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Acumen Pharmaceuticals (ABOS)?
The latest analyst rating for Acumen Pharmaceuticals (NASDAQ:ABOS) was provided by BTIG, and Acumen Pharmaceuticals reiterated their buy rating.
When was the last upgrade for Acumen Pharmaceuticals (ABOS)?
There is no last upgrade for Acumen Pharmaceuticals
When was the last downgrade for Acumen Pharmaceuticals (ABOS)?
There is no last downgrade for Acumen Pharmaceuticals.
When is the next analyst rating going to be posted or updated for Acumen Pharmaceuticals (ABOS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Acumen Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Acumen Pharmaceuticals was filed on March 26, 2026 so you should expect the next rating to be made available sometime around March 26, 2027.
Is the Analyst Rating Acumen Pharmaceuticals (ABOS) correct?
While ratings are subjective and will change, the latest Acumen Pharmaceuticals (ABOS) rating was a reiterated with a price target of $8.00 to $8.00. The current price Acumen Pharmaceuticals (ABOS) is trading at is $2.60, which is out of the analyst’s predicted range.
